

For Caitlin

The patient and I had an extensive discussion regarding the goals of therapy and treatment options for their Rheumatoid arthritis.

The patient currently has *** (Remission/Low/Moderate/High) degree of activity based on CDAI. We have agreed upon the goal of treatment would be for low activity or remission.

We discussed the following therapeutic options ***, including the risks and benefits of each therapy.

DMARDs: Plaquenil/Methotrexate/Sulfasalazine/Leflunomide/Azathioprine
TNF-inhibitor: Etanercept/Adalimumab/Infliximab/Certolizumab/Golimumab
Jax inhibitor: Tofacitinib
Other Biologic: Rituximab/Abatacept/Anakinra/Tocilizumab
Systemic Steroid: Prednisone/Depomedrol
No therapy

The patient's preference is *** and a mutual decision is to ***.

If the patients is not at the target and changes were not made, the reason is ***

Or here is another one on using for my plan in clinic.

Plan:

The patient and I had an extensive discussion regarding the goals of therapy and treatment options for their Rheumatoid arthritis.

The patient currently has *** (Remission/Low/Moderate/High) degree of activity based on CDAI. We have agreed upon the goal of treatment would be for low activity or remission.

We discussed the following therapeutic options highlighted below, including the risks and benefits of each therapy verbally and the patient was provided drug information handout.

DMARDs: Plaquenil/Methotrexate/Sulfasalazine/Leflunomide/Azathioprine
TNF-inhibitor: Etanercept/Adalimumab/Infliximab/Certolizumab/Golimumab
Jax inhibitor: Tofacitinib
Other Biologic: Rituximab/Abatacept/Anakinra/Tocilizumab
Systemic Steroid: Prednisone/Depomedrol

The patient's preference is *** .

Continue current therapy
Change to another therapy with ***
Addition of another therapy to current immunosuppression with ***
Increase dosage of current therapy with ***
Decrease dosage of current therapy due to toxicity on laboratory monitoring or side effect
Stop therapy

Mutual therapeutic decision is ***.

Continue current therapy
Change to another therapy with ***
Addition of another therapy to current immunosuppression with ***
Increase dosage of current therapy with ***
Decrease dosage of current therapy due to toxicity on laboratory monitoring or side effect
Stop therapy

If the patient is not at the target and changes were not made, the reason is ***

- Monitoring laboratory every *** weeks with CBC, Creatinine, ALT, Alk phos, ***
- If on Plaquenil, most recent eye exam:
- Immunizations (Influenza, Pneumococcal, Shingles, ***) and adult health screening is up to date as per patient report
- If on steroids, Calcium and Vitamin D supplementation:
- Most recent DEXA scan:
- Call with questions or concerns
- Return to clinic as scheduled in *** months, sooner if needed.